Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026680 | 0.88 | HTR2A (0.55) | HTR2AHTR2CHTR7HTR6CARM1 | |
| SCHEMBL7029794 | 0.86 | SIGMAR1 (0.57) | SLC6A4SLC6A3HTR2AHTR2CHTR7 | |
| SCHEMBL7031440 | 0.84 | HTR2A (0.47) | HTR2AHTR2CHTR7HTR6HTR1A | |
| SCHEMBL7029891 | 0.82 | HTR2A (0.50) | SLC6A4HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7026411 | 0.82 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6CARM1 | |
| SCHEMBL7025586 | 0.82 | HTR2A (0.52) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7032576 | 0.82 | HRH3 (0.51) | HTR2AHTR2CHTR7HTR6CARM1 | |
| SCHEMBL7032512 | 0.81 | CARM1 (0.57) | HTR2AHTR2CHTR7HTR6CARM1 | |
| SCHEMBL7029668 | 0.81 | SIGMAR1 (0.51) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7027762 | 0.79 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | SLC6A4 487/4885SLC6A3 864/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.